Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17920111 | 0.90 | CA1 (0.35) | KDM4CKDM4APHF8KDM2ACHRNB2 | |
| SCHEMBL9915023 | 0.90 | CA1 (0.35) | KDM4CKDM4APHF8KDM2ACHRNB2 | |
| SCHEMBL1709947 | 0.90 | CA1 (0.35) | KDM4CKDM4APHF8KDM2ACHRNB2 | |
| SCHEMBL16022889 | 0.85 | ALDH1A1 (0.46) | KDM4CKDM4APHF8CHRNB2CHRNB4 | |
| SCHEMBL25919388 | 0.81 | GAA (0.31) | — | |
| SCHEMBL17920012 | 0.77 | MMP9 (0.32) | — | |
| SCHEMBL15187247 | 0.77 | MMP9 (0.32) | — | |
| SCHEMBL17920016 | 0.77 | MMP9 (0.32) | — | |
| SCHEMBL15803261 | 0.75 | CHRNB2 (0.48) | KDM4CKDM4APHF8KDM2ACHRNB2 | |
| SCHEMBL20880284 | 0.72 | CA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686017-B1 | AN OPHTHALMIC COMPOSITION | DRUG DELIVERY SOLUTIONS LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| US-9914755-B2 | Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized | ALLERGAN, INC. (US) | 2018-03-13 | — | — | US | disclosed |